PODD - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2020 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to your host to Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

Thank you and good afternoon and thank you for joining us for Insulet’s fourth quarter and full year 2020 earnings call. With me today are Shacey Petrovic, President and Chief Executive Officer and Wayde McMillan, Executive Vice President and Chief Financial Officer. our this and the available XXXX Investor section of our release on replay Relations results XXXX guidance of the call press and discussing the Both website. will be

inherent SEC like explanation refer Before we made of Insulet statements to limitations differ forward-looking the the during from inform of maybe our that of call could certain cautionary by this to filings course and statements. begin, detailed statements you current the for would a I materially such expectations. in Please

and We and that discuss investors, performance performance, measures which These what helpful effect also to interested constant operating non-GAAP will the we other from respect are management of as operating believe financial exchange. revenue, period to namely measures uses income they our analysts align supplemental measures with our is as currency in parties adjusted excluding foreign with measures assessing revenue period. growth, adjusted operating EBITDA, of to performance and our

Additionally, over all financial basis dollar currency that, turn on of will year-over-year regarding unless will on otherwise changes revenue call a I a reported exception the With be with the constant stated, rates, and to be which year-over-year Shacey. basis. percentage growth will commentary

Shacey Petrovic

differentiated executed delivered marked guidance. strong share successful strong for face and our will Deb. then year advanced of our challenges, open discuss the the our we your This of people while the today’s customers fourth our of we call, past XXXX year, our our consistently clearly we and strength imperatives. to clear finish Insulet. for call value results Thanks, mission a I indicator for other, accomplished is strategy, the very our and more new another strong and any culture. the committed And afternoon thank of we the The Wayde the only and proposition customers, Together, we demonstrated joining but of our a financial not Good serve. embraced growth key What each and in other, questions. In resiliency quarter XXXX technology. introduce extraordinary core will we a our strategic will our staying supported pay-as-you-go of our key communities all reality, you us. our XXXX our to durability model priorities. also On accomplishments and have and loyalty than

One team as adapt in ability incredible greatest to particularly the our an changing year of an an perform strengths our to environment. of showed compelling and Insulet’s past and customer delivered was and commitment customers learn, is rose unwavering growth. centric another ambiguous our executed This mission-driven this culture. and year to evident challenges with We rapidly

XXXX, towards In entered mission a Insulet we beat and drives and commercial passion. the people face We our Our lives diabetes XXXX we challenges. clinical a innovation employee In conditions over annual for upended given global strong on delivered momentum Omnipod the X working fifth and launch and with and addressable innovation, with goal same of unmatched and a commercial growth pipeline every consistently we remarkable consecutive with operational track XX% COVID, market the with remains revenue and growing year, of the expanding initiatives. achievement, market. improve this our didn’t miss advanced

U.S. lines. product annual the both and our pre-COVID quarterly and In Omnipod year international XXXX revenue of for expectations. achieved beginning fact, finished We of we our ahead record

were customer starts quarter also by that U.S. with We higher fourth customers, history. completed of quarter a year number in new Insulet’s any than new global the driven record

XXXX. new certainly overcame customer impacted during While our we the finished pandemic’s and additions it the year of most global strong challenges,

overall serve to has our been outlook Nevertheless, growth. revenue financial our slight as look a impressive this we to and As XXXX, performance will remains headwind strong.

around and centered excellence. expanding we and imperatives our awareness to consumer turn will access are customer driving global I and awareness, access operational with innovation, strategic delivering what the addressable start and Let’s growing doing market focused our deliver experience. best to

existing too that is don’t Omnipod. a many traditionally Omnipod’s Our Outcomes There barriers simple, with access because unaware to limited diabetes far many compared living are to breakdown people for have are being or benefits are other primary therapies. goal of a access experience We access prescribe has factor for making is been an physicians. provide too it while affordable Omnipod easier product simple, our easy-to-use and and costly. complicated customers platform unmatched. simpler too form customer and that offers broad, to discrete access

clear of leading and loyalty delivers. retention Omnipod value Our customer indicators new industry the starts, are customer

new daily to new of XX% from continue up fourth in our X, Type and the of XX% between Omnipod attract QX. injections. our customers We multiple approximately customers quarter, were And XX% from

last current powering end and only Type of well is also as Our fourth represents we marked start our secured covered X X, to coverage with and of globe of both technology our approximately DASH, success, not from the as move Omnipod our next DASH, By access. mobile system, for the most individuals platform MDI users the Today, up on Omnipod DASH. new pharmacy and Type generations, our expanding the quarter, quarter. throughout it for Omnipod significantly for U.S. XX% had lives customers attracting

access dramatically our with increase we U.S. deliver is benefits continue awareness our increased While awareness pharmacy customers market model people we is The providing Omnipod underserved the growth. diabetes. to through the driving and pay-as-you-go of remain Omnipod diabetes also channel, focused to we on and easy living

have us advertising leading direct-to-consumer The been the great to and has positive. recent of key Our campaign with read pilot our insight. provided reaction indicators, early

continue to the will progress decided been step only marketplace. and have our be year. integrated the have back, gap closed, Omnipod adoption forward despite surpassed. on strong product CGM having we that retention throughout all look not will you Taking This in advertising to We updating not a efforts. technological incredibly it a our to year, support So be

with we not next innovation. of our have know been customers could customers of unmatched designed the our waiting for improve our our people insulin control. freedom verge DexCom, future for partnership automated introducing to and glucose consumer-focused our and deliver and Omnipod We to transformative technology. evolution We simplify thrilled are system excited, X, more be on be diabetes management living greatly in delivery and insulin to with is

prospective with to number from the ability every be entirely AID on than there will is wearable tubeless to from stop will change or the the one days, control first current We pod need the X algorithm system And a smartphone. the pod. therapy. be Other no a personal request pod and customers the disconnect

system, component first and control. dramatically Our smartphone in provide system to remove of we burden means simplicity and resulting of reduced use. full the This be ease can improved the an will entire

technology. Our first them goal to Android much is with less. much to X and near will diabetes more customers are to how phones when always ask system. for manager not even mobile connectivity all provide from personal doing on will monitoring. X, Wi-Fi remote control parents real-time SIM Omnipod launch do ensures receive customers constant this their will data and with a backup our allows children our know and a This to With Omnipod

to X to a about how glucose heard be have real-time. periodically from able monitor control in it is relief to children of their many have confidence Omnipod and in much We

is spouses trial their lives the we us X. participants people living they since Omnipod are that on technology and X have revolutionize sleeping believe Omnipod with disruptive result, finally parents that starting insulin-dependent of families will are and told market that a and As better diabetes. the

to with gives our majority at Omnipod try track and first customer be us X-year this This half know customer model. or our We for will free upgrade Omnipod pay-as-you-go to the on launch year Omnipod of our anticipate securing at access therapies, payer X efforts will will barriers secure any same limited upfront, of users eliminate commercial pay are have with they United this DASH freedom other broaden with to in under available coverage, of fee commands consistent of We Aid States as for with accelerated drive focus access. and be $XX. and Anyone will a X with will pharmacy parity the in is this customers year. Omnipod affordable customers of offered X existing locked a into DASH Omnipod tube a monthly a have be on at our premium, Omnipod coverage X majority Like DASH, time only is we co-pay XX pharmacy a time access. coverage, coverage not U.S. launch will nor and Omnipod the the we period level system while pump have Omnipod limited Pricing broad adoption in channel. trial. pharmacy contract. broad for in our will the since in X the an even price be Omnipod can Unlike days

a diabetes driver be living confident consumer changer will and are We broader access. will rollout of a game be commercial for Omnipod people believe primary X the with

We than ahead and chain our market are to build have invested more supply prepared to and operations demand. manufacturing meet

submission plan continue up patients of we value on X completed young XXX% that have to the plan clinical to study, an X evidence elected children is a these additional expand expanded we to FDA. and As Also, we this groups to markets the clinically delighted are robust the the continue our X X X’s enormous of children. deliver study settings. to to extension our launch, goal many enrollment can within broad continue Omnipod The including Upon our preschoolers, continue had further young and have with to and have to for can indication feasibility by expand our that that data multiple Omnipod highly indication road ongoing study’s believe our conduct support therefore, build anticipated product, we completion, of for to ages compiling we of indications. to share indication heavily year. are pivotal applications gear Type to clear a And XX This completed we to for recently phase. the value for our We Omnipod to an and and work the as studies invest map, for technology study X. We, trial we continues. will XXX% provide preschool end into

should demonstrate to pivotal at data any month. indication, improved and the Lastly, we Omnipod just life. outcomes Omnipod how quality forward is perspective, improved X X data it our pivotal of conference Endo is look pre If powerful our from for presenting a next clinical

launch rollout about beyond advance remains But our priority. We successful of are well and map Omnipod incredibly to innovation extends AID continue our top road system. we also X that a excited the upcoming an

our map, data and development particularly science. In the product support doubled robust fact, in development of in number of software employees areas we XXXX, road to the

in to committed our value are for We years investing come. increased to deliver to future to customers many innovations

unparalleled drive interactions of with advancements, of through to insights designed programs user algorithm and sets smartphone innovation on simplicity our value working improved integrations. outcomes data and are from We and analytics our choice systems, user growing our sensor and

in offerings extremely We millions too are beneficial uninformed far to and diabetes our the Abbott CGM of globe. deliver a X both By expect adoption are be we are Omnipod delighted the is generations increased to Their as Libre This global market future treatment that remain many further lives of line X people efforts. in underserved CGM segments. with the committed platforms, critically long the about innovative working options. offerings around partnering these and together, integrating their and people X with and Omnipod to of Type in Type improve DexCom remains to helping drive multiple

to Europe fourth East. the and Now new the entered turning within X countries expansion, Middle we quarter, global during

week, XX we year. this today, insulin-dependent on the estimate Australia this we people countries In diabetes. serve to are living Just million in expanded plan and Turkey to million launch XX later there into we with

Omnipod. in a widespread large focus market, and lives of and and strong greatly provides technology to our capitalize simplifies life. We on to we provide to know quality outcomes A addressable are given better simple this position access

We are over go-to-market a time. internationally geographies and to expanding in plans our enter manner larger are building targeted strategic and

market innovations grow like continue total We bring X our expand to we addressable and market therapies. Omnipod further as to displace legacy will expect significantly internationally,

progress throughout made support kept remarkable. facilities our and global we entire significant global year and expansion. production, met chain investments our high-quality demand past to levels. We not maintained in We robust only operations this the and And the made supply open a in innovation have manufacturing was product our COVID, face pipeline business of

momentum and across we and China high expanding a line, opened U.S. significant on note with facility also and third our We new a in manufacturing manufacturing our manufacturing entered XXXX quarter, supply delivered redundancy. strong finished installed chain In our business. another year the further summary,

lives Our call and people in our will a competitive major X will mission improve the upcoming with differentiators remain unparalleled. simplify Wayde. launch marks of to position, and And I over our to strengthen milestone Omnipod now the the market diabetes. significantly turn of

Wayde McMillan

Thanks, Shacey.

completed Our fourth execution. solid growth quarter another of and results year

pandemic XXXX Although with with we we momentum. through strategic positive advanced our challenged This meaningfully year, the XXXX, entered past imperatives.

growth, million was million delivery guidance Our of growth guidance of million. our which while ahead above XX%, all quarter, was our to also focus revenue the total revenue and strengthening driver to mission. finished our further accelerated In value of profile financial $X continue for slightly $X above outperformance Omnipod The expectations key growth range. drive and range. $X our this by fourth over stakeholders Drug significant our expand for invest margins will we XX% delivered of

starts initially the quarter. headwind XXXX, negatively impacted customer estimated, pandemic new was it than beginning largely the a in global less throughout While of second

a reminder, this revenue the half created compounding a XXXX. in of impact on dynamic As second

XX% impact revenue was U.S. U.S. quarter. added were lessening and In Looking customers in We ahead, our to will Omnipod favorable encouraged the QX XX% both new regions, than customer to continue sequential QX. degree. did continued grew combined in more improvements XXXX, new XX% we we a global estimated international expect impact see revenue than approximately expectations. the to on starts more although beginning-of-the-year fourth off as in we with quarter, in the in of the the a effect of almost fourth

XX% the Omnipod customer grew the performance volume. U.S. represents our through our by was as mix customer base, over over in our drove starts, U.S. new into channel. and of volume DASH and continued benefit adoption Our XX% Omnipod increased adoption DASH to total growing we of This pharmacy increase the driven shift a channel pharmacy. in continued line Omnipod the pharmacy top of DASH we solid

reduces delivery Moving for prescribe the of benefits business revenue remains and provides on more performance in barriers a is easier growing margin our number expectations. Not expanded again for and quarter, our expected. forward, for customer to revenue in to the Global XX% XX%, the quarter. in to it shifting in shutdowns base favorable representing basis COVID drives out-of-pocket predictable a timing point also line Europe driven of decreased XX.X% model a mention European than many by Omnipod payers. XXX and more fourth and more access due countries. key stable Despite were physicians. is customers, pharmacy efficient was low, grew attrition related Gross priority as increase, Omnipod utilization Drug the in to our International production. costs for with

U.S. ongoing our Our ramp into continues new well gross operations lines by our automated mix as manufacturing volume driven of expansion be the improved as primarily we further benefit to channel. pharmacy as margin the shift

quarter we in basis expectations XX a headwind due a was the to a costs. XX contingency favorable and estimated and to expenses currency late in our the mitigation within fourth of Operating positive point we’re pleased terms by December, $XX European partially COVID have Foreign related and charge former basis a above to were reached the offset from related disclosed with safety distributor payment tailwind, our range. million resolution our point resolution

company. well Excluding our as award this in as a all environment, were expenses line stock to for a to employees our very operating challenging expectations, as including XXth with charge, their anniversary execution in a mark

in phase we and in will R&D we one-time more As and our with which now and This an our XX% exciting as also incurred future, the be timing for was relating way especially selling a projects, to was of employees charge XX% result, Omnipod we XXXX. to as prior to expense The a enter offset X expenses EBITDA year. new a in our down in due QX, company serves million of bonus. expect grant somewhat occur equity a by $X launch marketing invested lower this adjusted the margin from

continue business, business and to growth. increases innovation well as as scaling awareness, We our in throughout including to invest advertising global support our brand our

down company For of XX% annuity achieving we model. of year total the basis expectations. growth illustrating revenue included and XXXX, durability the delivered further a XX strength related This Omnipod revenue of costs our another of gross total and with full from and unfavorable achieved XX%, year, and point and XX.X%, our in margin a currency points. revenue impact of points growth favorable XX line COVID we basis impact basis foreign record XX In

with the guidance margin Excluding finished we year. gross the of at target COVID on related start our the original set costs,

to capacity demand benefit scale We are global seeing strengthen growing manufacturing global capabilities the and for we meet our increased clearly as from Omnipod.

the also the through U.S. sold Omnipod are DASH from pharmacy seeing We channel. mix benefit

For the EBITDA guide to achieved from of our spend. we adjusted XX%, margin full up of exceeding year, timing XX%, due

debt strong interest cash XXXX with and in with in a and remain to expense. liquidity, cash maturing our ended XXXX cash Turning we investments. position and in earliest low $XXX million We

financial sound in gives strategy. long-term support of position growth continue invest us to our to flexibility Our

our value to sustainable for foundation and is for our XXXX, outlook turning growth Now, long-term, clear. creation

still customer Although effect the starts XXXX from dealing XXXX. on will global pandemic’s new we and be into with

the by markets. in mix the driven by For our pay-as-you-go volume Omnipod growth of XX%. total Type revenue Omnipod XX% Omnipod pharmacy we U.S. and year, growth X expect expect XX% total X growth be to growth XX%. aided and differentiated the XX% and This of By expanded full access increased in awareness, a investment with of our product company revenue will to benefit, Type to Omnipod revenue DASH, in line, model of we XX%, adoption

of half the will the ramp X year. the commercial we of as benefit from limited Omnipod launch second We in to also begin

This part expected revenue offset of starts current in to Europe will expect markets. growth in the be further of XX% the impact by the and our driven XXXX. persistence XX%, in well by International growth range We customer the Omnipod pandemic from global full of in new compounding as lower as XXXX year

encouraged starts strongly new recent impact improved of U.S. Europe customer COVID been has we than the While are that as in more we felt XXXX, the exited

an expect range of drug increase in decrease Lastly, current partner’s forecast. we to a our XX% delivery the be to on X% based

our expansion into year Omnipod U.S. at target to from expect operations. moving we continue for global mix our pharmacy by manufacturing XX%. stated to from and now positive full to margin driven enhanced margin, This growth, achieve gross of gross will volume the be XX% Looking the XXXX, benefits

to operations. We into sellable Our efficiencies currently scale lines and this our build two third expect our have today sellable and to manufacturing teams production year. producing product continue begin line

In capacity second our capabilities contract the addition, two that volume an our China manufacturer our and balancing extension in in is redundancy while increasing region, of between sites.

position a margin this We drive expansion are in solid to year.

the During XXXX, will operating consumer-focused X a as and note the marketing position we to expenses strategy. Other line expanding from large see as support to and R&D in largely revenue upon our and shift with build X is company, markets. commercial item that One to we our and clinical shift. we access rise product. X in expect our a similar underpenetrated invest to developing differentiated continue will efforts to growth, and trial mature as Certain shift and Omnipod Type Type activities will innovation

million $XX to from As estimate SG&A costs a result, will XXXX. approximately shift R&D in we of

X.X% with growth our We profile. our investment significantly This operating continued digits in in range, to XXXX. expect margin from balances strengthening low be up XXXX double for the financial

as due our as XXXX, last in increase of in to we investments launch from and support to X, capital Omnipod capacity year. of manufacturing expenditures to expect growth the well manufacturing carryover continued some and Finally, expanded fast-paced operations primarily expenditures

includes Omnipod to revenue of XXXX, well expect international the on company Turning By X% to growth XX% we related growth total growth Omnipod carryover XX%. XXXX line, of global XX% reflecting XX%. starts to continued as as internationally. impact the to XXXX of in primarily revenue Omnipod product and quarter pandemic of XX% U.S. This lower growth new first revenue revenue to XX%, total XX% headwind a of customer expect we guidance, to

continue conclusion, In XX% in revenue market revenue how XXXX. track expect in market. We expect to We X are strategic also on extraordinary, million. need over launch remain and unmet as team persevered Omnipod imperatives legacy Omnipod $XX in our million proud few the drug delivered to growth, $XX we of delivery and a The we therapies to addressable of our to grow replace we advanced further is our diabetes months.

are priorities clear. Our

the shareholders expect are diabetes capabilities the and community. to innovations we will investments we us create long-term call we the operator strong and We drive sustainable, are to With building the allow and deliver that, future the over turn a growth pipeline for making of will Q&A. value to for long-term

Operator

from sir. is you, question Wells from Larry Our Thank Please go ahead. Biegelsen Fargo. first [Operator Instructions]

Larry Biegelsen

and congratulations to Good afternoon, year guys on the end nice here.

just of how that on X. limited Omnipod all and course Who guess, going have going XXXX? launch access to of access one is is what is the Thank I you. Shacey, rollout So a who and for have mean? me through the evolve to

Shacey Petrovic

now Larry. we great the in of share Thanks engaged under And us Q&A agency. of release that’s the are the and first great for been I want launch in and limited in the into Collaboration review on behalf confidence gives Sure. has market quarter. question, what did to part that

things. are limited to test a release, So, as market into few we we looking move

is governor, opening remarks, primary as to my the I in said access. going So, be

the that the experience product existing our product for people the to and users are pump users to customer looking work what access as on in injections, on the We to successful the to take expands in the the we limited who are but that’s that in and access and coming for training qualitatively access of us for be on time just for and have to continue underway, market going tube we that are channel. expand pharmacy is to multiple product. be to that we will the transitioning will broad to scale indicators be primarily. market is are to daily release, so will looking establish just That But terms experience, ready transitioning understand experience for governor it’s

systems, expect is just to the our and want those all are test training, groups. to we that our each of we to it are support going as we expected So of clinical going in them our as going product experience

As that this next. as later either access, into year next rest and we what question. through and have year us this can we the full early that’s move We on validate or launch expand to will establish of we market the Thanks.

Operator

next Robbie the comes JPMorgan. line go question of Our Marcus from Please from ahead.

Robbie Marcus

at adds one Congrats through great am was something I coming that X on out make growth growth then a Great. Omnipod ballpark. little patient XX,XXX. One, into the new what my throughout year right from sure assuming two for to I impact the at XXXX? are I squeeze as just here. look and cadence are how want And you over quarter. year, in that’s over you for Wayde, to expecting am number the you to third cadence new Thanks. Shacey, fantastic. going coming I a at that XX% was patient the quarter XX,XXX

Shacey Petrovic

do to Wayde, want take Yes, you that?

Wayde McMillan

starts over for to see. XXXX, in That starts new Thanks to question both tough absolutely impacted QX for really Yes. just happy Robbie. in right. international the are Sure, that the to from can even improvement so was XXXX we regions The was in I start first it. the you us very a see pandemic see the improve year QX as U.S. customer new was and and customer XXXX year, middle sequential Actually, improvement the the important in it, comp. certainly us sequential importantly, were and saw We had prior record-breaking QX. quarter of to we right,

as now XXX,XXX We to are in specific release, numbers shared earnings customers. customers, we global our not going on have comment we but of

point, And said be I a you. new start on release. as limited So, Omnipod growth a remarks, then Shacey for X, good prepared for will it patient her data it’s think in

lot monitoring the developing going scenarios one. a so And things. on we year to of on we depends access. great as in what how want really first launched ramp. said, the lot half well It be in as are of and a We user Shacey both running it the get that point we here job then a And is as of do experience there to

said, around like it’s the none market the pacing and be again, next so Omnipod time over that getting up two just Shacey ramp diminishes those year. our And that excitement of things X into will

had a have gearing up from for have We our couple and are been customers now. immense Omnipod to of X years interest teams just launch an and

So, building, the lot but most we successful to the that excitement move keep the half we in of half the And lot to the of of is through ramp we into have year. second want of make limiting ourselves of end momentum, can. we as check that sure part launch first and the

Operator

you. Thank

question next Johnson comes go Our from Baird. Jeff of Please the line from ahead.

Jeff Johnson

through reasons a there X of even a officially two about. all if term know X X us for again of light afternoon. just could Wayde, that? if investment Thanks. guiding you. still things parter term over and like here, bit But expand forward Thank I growth ask, lot A ‘XX/XX you. do intermediate the X-year gave to help dealing XXXX? plan kind with again have the guidance for I some margin sustain looks about revenue once then longer Good there would deliver start that talked maybe mid-teens maybe kind to margins period you out above you to to on think longer XXXX fall in you operating but calling year, uncertainties. you above year let have to term Omnipod and on guiding me longer investment maybe XX% like not focus, anyway we just I light there heavy short this next Can past as we guess, the of years think the COVID this by X-year years, in by give going about and kind well to like It going to year. going $X billion Do for that are is outlook? had expansion few you a that your us this are margins revenue we things guidance and revenue in this are comment margins get I for But of with

Wayde McMillan

until X. long-range for your are launch lot side real robust planned excited Yes. It get ourselves company. we not of are of But Thanks time spending Omnipod can went question, what a to are the well. a going we for I update And as it through on provide it we Jeff pivotal other about the a and to is deliver. planning strategic we session here. long-term guidance

ourselves get Omnipod quarters pacing few for are X be then we from a we we under So and until our update will an long-range there. plan belt to the updating with

a which to highlighted particularly we internationally though, international the U.S., include is because see the do things and the You more. guidance XXXX, persisting XX% really for feel which headwinds in strong, U.S. pandemic the we in here guidance to XX% important story less few for

have prepared the We in guide covered remarks. lot a on our revenue

to we at And will be I think end is then will margin the of is year. XX% end the we QX at There some is quite there and to understood low through year, go make pretty build dictate well XX% going gross high we XX% If that don’t We committed XXXX. a to the XX% XX% time. XX% into we to in range few at end. expect this range are should drivers or whether XX%, we to the that up over getting that. to be below to as phasing

of question, your that Jeff. I a was part So think

our they bottom will time. are thesis about we And we get As line that to we well. over key of confident think and XX% mentioned the financial then you a as component are gross margins,

for beyond, to both and That’s continue one should unpenetrated on very we up significant is step ‘XX but have differentiated large here, X to X we XXXX not everyone guided invest the That investment market, to strong beyond step operating sure double-digits. XXXX, make a we understands up Type have We this our area, in in our low same from position assume Type while the markets. that here is and want XXXX. thesis to very to capitalize guide a margin not

marketing. R&D So heavily to and us you to particular, selling innovation, clinical, should inspect XXXX, and in continue in beyond invest

as support we efficiencies G&A scale driving be to going are functions. in We and

with it to that build not I so over directly operating every question, think margin X%, more to continue to this are year And time. we stepping margin from up ‘XX. expansion up help to profile year will your But we to annually, a probably financial strengthening like will back the Jeff, like us, come gross tick but ‘XX just along

years, So and I we future did are here our we giving balancing investments are sure thesis fully over guidance that time. the financial understands but strengthening not margin for everyone our to with our operating investment continued profile want make specific

Jeff. thanks So,

Operator

you. Thank

line next the Morgan comes go ahead. Please Our from David from of question Lewis Stanley.

David Lewis

two mean get question and that the I U.S. XQ. a Good for on Wayde, discussed globally, quarters little stronger of on we back want ex-U.S. congrats in step nice recovery, European of were afternoon. number, a Thanks did come people Omnipod versus absolute than down European think commentary guidance the a little a first first to the XQ in back the will your obviously, sequentially number and sort to business the better last you taking or kind implies but the European the expecting weaker of quarter, dollars quarter. is just for I based time take terms in guidance see recovery the

you? resurgence just you what in beyond guide have guide of ‘XX anything seems in seeing perspective, some going from suggest XXXG, competitive it the sort were that just doesn’t ‘XX – guide what a you’re continues. improvement Because Europe seeing terms there the is on and So first quarter in the that Control-IQ, sorry, of

so could be Thanks out, it much. So great. would if you flush that

Wayde McMillan

Good to in guidance, Thanks. this with really of on more prepared of in fact, peg pretty lot a outside you that. the reason. because, this U.S., to The We of at lot was off difficult guiding in is step-up companies remarks, for least us. as obviously, and and the a are trying peg, your our progressed of companies on The of a we’re U.S. time question, challenged our beginning as side know, tough a QX. U.S. in only pandemic And And XX% significant expectations lot as better and we the year. of saw Yes. we improvement aren’t spend for David. specific we’ve the said through

of year and to expectations, quarter for our almost ever. So us back a it was beginning record-breaking

think the confidence both model. that in annuity feeling will it guide. than And of lot effect a is was it a International, as of high growth like so end we be strong it And guide. At compounding dollars the our in and of the U.S. low it’s it’s – you XXXX. more said, end, of mentioned, higher all you David,

in the into of further three we’re it starts it’s persisting half in new heavier pandemic impacts, first pandemic XXXX. unlike more So to of the XXXX, feel U.S., the internationally. last first of the because XXXX anticipating internationally half going And were quarters impacted then the the customer

into numbers. compound continues that So to the

of got countries. Having the international We’ve So got we the DASH quite momentum that, our rollout dramatic. got have our it in regions said across X lot all all too, have – business we a new is internationally. new

there force investments making in investing sales We’re we’re also and pilots well. as expansion, in marketing direct-to-consumer

us to confidence gives strong face the double XX%, internationally. the of environment what digits, a that’s XX% to in So guide to challenging pretty still pandemic

what of at throughout that’s for this the with here certainly and we at all. it insights And year. to So and as will you point be track we go happy comfortable the year providing the guidance start we’re

Operator

Thank you.

question Our Raymond of from next the from comes Please ahead. Bedford James. line Jayson go

Jayson Bedford

afternoon. Hi, good

any you Thanks. there it? recent? quick XXXX XXX,XXX been Just XXXX milestone a or has retention, in and attrition the The a for however recent or one of to want just me. that Was guess, I users, event how frame changes

Shacey Petrovic

are it’s Omnipod. organization. for milestone. It’s Obviously, Jayson, the we relying million yes, users be a thrilled That’s exciting Sure, all really celebrating recently-hit on of to estimates. milestone the X.XX

did a behind the strong anticipated there in been That’s it So have as or steady. event. we XXXX really was of that changes And that, I always utilization. to want have predicate obviously, because, remained attrition with Those not but actually terrific, attrition the tick pandemic. didn’t of up face in in that the that. pandemic, XXXX could the And of impact we that’s anticipate potentially, really the performance of driver see the part we

on So customer that’s just the the and business news great loyalty. model

Operator

you. Thank

comes Please line ahead. from next of from the question Chris go Cowen. Lin Our

Chris Lin

thanks for questions. my Hi, taking

I with one have this was Omnipod eminently. you iPhone? Loop revenue the you. specifically, upon Tidepool, product? maybe and launch? commercialization curious Tidepool. could XXXX seems factored do this impact into algorithm any Thank approval if It you on anything FDA And could have for And receive like how your to Omnipod plans thinking more Just guidance related

Shacey Petrovic

Sure. clinical with development Thanks question, the our Tidepool for primarily been and one. product has partnership Chris, a

point their supporting at Tidepool. and submission have their we’ve So with commercial a don’t been work. We agreement this development regulatory

be I it’s tremendous to worked say still that. that’s a out. will do to So undertaking

under we with So us. we lot that there on a we iOS have Omnipod But working we the have platform. said of is that still said, here underway way of work ahead or are do X work –

So I the support about think we’ll going their our really it excited who’s terms with Omnipod point. That this X. priority be market their we’re hit seen submission remains certainly in to efforts Tidepool’s first iOS, remains to continue to And and at development. and of

Operator

you. Thank

Our line ahead. comes Wuensch from Joanne the from of next go question Please Citibank.

Joanne Wuensch

of to seeing some if taking and seems of curious it’s I’m for is market? towards I was to you or DTC just campaigning about development sequentially. the your XX% thank XX% step-up natural And the a of if X metric. question. why a heading that’s curious That and just that, that we’re evening nice Good the be Type sort

Shacey Petrovic

we’re X States. you from X benefit over would product that. responded is a can the the estimate a who just users million people as lot just and And of group that simplicity X the have We United people the DASH two living one, insulin-dependent yes, with of there awareness so increased benefits. some driving are It’s about know, obviously of really in diabetes I Type product. just Joanne, the so things say continued Thanks, excited segment. Sure. Type well of in to the that

advertising as unlocking that. part so what’s of And

other The we costs. under line of a more to availability such in injections business in allows And saw multiple as with month differentiated really affordable pharmacy, in increased that That is for in thing an this cost with people daily is example. step-up the the drive the you access. access $XX out-of-pocket model it

that’s constraints segment. broad in drive establish to is it been And affordable injections. broader of cost our simplicity that more incredibly doesn’t that we Type access X thousands of the millions That’s technology line patients, of other the access in to of So hundreds the tune multiple of we product, of patients. channels We the our affordable with just strategy we sort for and bring the as believe have into really. daily how access not exist

growth. that’s And X what’s driving see think we’re the that. been so excited and part adoption to I And of Type

Operator

you. Thank

Blair. of next William the Our Margaret line from question from Kaczor comes

Margaret Kaczor

for I’ve Thanks point. to a Joanne’s Type the everyone. questions. Xs on got couple Hi, taking the of follow-ups

given So have are XX% X a patients? utilization can these the needs referenced how insulin that sense you of Xs to of the are base the patients, guys Type percentage a percent that big a you some Is under call Type Type give around us X? as in Type anything pharmacy? X maybe it for on they versus coverage what And then installed close for

Shacey Petrovic

why. Sure. Unfortunately, I’ll have visibility. Yes, a add. explain then to we I’ll start, have of don’t color may lot some and Wayde

As point we we visibility less to have at into coverage. utilization more this channel, drive at pharmacy the diagnosis

because, through channel. of is the a all reimbursement age And little or our a is pharmacy us X living Type of XX% with obviously, so for over And bit that people Medicare insulin-dependent challenge XX XX. of diabetes of the are

you channel the so can of Medicare imagine in overlap lot a Type And that behind our is there coverage X the segment. and pharmacy

In XX% Type X pharmacy and the a all access, coverage. commercial actually between in X Type coverage. a terms number of is for isn’t distinction There channel

and Access, given both segments. probably for is is for And the very the user. Medicare coverage in out-of-pocket number at strong progress we’ve Medicare that good $X particularly made, So

X access Type X really a user really the Medicare Type the it’s affordable, broad in channel, the So user. for particularly pharmacy for

don’t contributing a so visibility of with that is now base total an is of because ago bit pharmacy years all for channel. gave a us. unfortunately, think what have we great and from I challenge. few a growth for So the growth. for much updated payers This driving been into comes great to users, great number we’ve But the right And we

Operator

you. Thank

Matt of Piper O’Brien the Sandler. from from comes next line question Our

Unidentified Analyst

for event? And you you Hi, that provide could be of were is the do later are more an how come Omnipod over with year isn’t compatibility half limitation this an or that the this will you iPhone, think We will iPhone sure uptake? hoping on making a a on having for Karen update Matt. XXXX of population that X,

Shacey Petrovic

Sure.

additional of an have not time integrations updating update said this times and we’re the platforms. that market, for and all on want going in to sensor I will work can the lines X innovations really couple multiple follow that last start to calls around to Omnipod is give So underway. we timeline. phone get then the We additional But

mode teams phone a SIM for back and you the Samsung with phone constant This will Omnipod users So data all we to PDM iOS gives be working envision very of X. And reasons. control. will We your connectivity remember, pod benefits pod to that in up But or technology. to if a X people two in remain pair can a phone don’t you and you’re every only pod. provide user this is on talented One have factor and limiting we of a PDM need a using announce every time for you control otherwise, a days when your Otherwise, phone meal. automated to or all of viewed the is our your apps your able the on and of your algorithm on via be PDM, because iPhone. data without closed-loop

that going apps iPhone. on and of ease your through visibility our you’re use still all to So get of

experience going Omnipod full as get with to for working So be quickly once we control it’s them we a to user we’ll update very and to Apple we’re great phone think users, and market as possible, X. get hard

Operator

you. Thank

line Our question Jefferies. from Petrone the next from Anthony of comes

Anthony Petrone

And on would lines when gross a be among tailwind? parents and opportunity One the A you quick that preschool Omnipod the to get you. automated preschoolers reach large opportunity can would would for and Shacey scale, thank Wayde X? U.S. characterize the you demand China be quick is? solution? how one for margin automated Hi, Wayde. those And one on quantify an the quantify for And maybe on for Thanks. one quick how

Shacey Petrovic

X. group this leader that group smaller as outsized pediatrics. But Today, Thanks, expand and I can value to segment. to of is as well of to preschool segments, We X value importance to segment, tell our see both Anthony, we a a the for I the ages an ability terms have in This market the segment. the the size in are it’s don’t maintain so this Insulet. technology of you

group, discretion You to about a that particularly differentiated Omnipod of benefits X tubing and to X for going technology device, with when of insulin and delivery. it’s without think for we use it’s combine large for active automated having the small this feet be this children versus the young a of powerful. segment, today contend integration ease And children CGM and the to active incredibly

we’re the and that and population. that our we indicators phase, response important the to the to of product users really on in going So on think indicator and the a extension all know, this XXX% completed have trial based the feedback from winning trial moved strong participants, I

Wayde McMillan

we the but it’s sure our Thanks Anthony, customers. well. continue critical capacity products make we have globe our the the on and not to that can quality Great. only strategy across overall redundancy want given question strategy, as servicing also operations that sure to to make for we

salable And the line we along and from automated the product on in lines so will this now producing question, your third be a U.S., producing installed have that two year.

you then legacy China which in China So doubles up second referenced in XXXX, legacy we manufacturer of that And the is lines, facility. stood during which capacity out other more third-party our our also the that facility. fact our a capacity than doubles China the

that ability facilities. margin single tailwind, for to gives us. as well balance important over And as of the increase between it largest is actually, redundancy gross is improvement capacity that all us the significant it the time. So, margin The our driver, of gross together

through the is have the costs so that plants, that volume particular, variable put us. to more that efficiently mostly put and in become we we begin fixed be will more margin we costs. most for all efficient and tailwind we but As has volume will manufacturing The our through U.S. more limited automated there facility plant scale a gross

and good margin get us. drive operations of are number the favorability quality to product gross all reliable our customers to So, strategies one, a designed, also for product,

Operator

Thank you.

comes Matt the line Taylor from UBS. So from question our next of

Matt Taylor

taking the question. Hi, thanks for

So had integration. was question on I you avid working these mentioned sensor

just to about and the can? a out So more I partnership there timing you you was the could that that extent flesh hoping any talk and bit

Shacey Petrovic

Sure, Matt.

dominant continue awareness, as adopted to they they markets. for excited be partner us. countries partnered of We’re a has are certain they are international with shareholder. product to been are drive Abbott. Their in where terrific use and ease And particularly a There

lines we I generation our with be into until As the mentioned, giving get market. updated out time DexCom current we won’t

And that, the drive. about partners, that adoption. Abbott, to excited They value real-time going adoption market. they users. insights Omnipod to bringing very fuel is and helping that’s are We’re driving, are transforming But to sensor DexCom the both are

so important are the very And to both to us. partnerships both bring our a long potential see line with we innovations DexCom And of with and Abbott.

So we working are on that.

we people market the that is Just focused and Omnipod have on X like to the underway after of we that get iOS, had excited update work and teams market. integration, to

Operator

Thank you.

line question So Stifel. Please of Mathew our from ahead. the Blackman next comes go from

Mathew Blackman

very question. for afternoon, much the everyone. Thanks Good

the relates started to Type from Type meeting that looking ENDO it even Just in patients. a abstracts on and at website. how to enroll? It month, beyond just inform the larger the what presentation ahead is thinking X you X Bode or Can looking you us X next some Omnipod the at remind also there meeting helped posted study, study study to the like Thanks. looks just of Dr. pivotal early is

Shacey Petrovic

Sure. great question. that’s a Yes,

be study X. some Type Bode So from in results early presenting will feasibility Dr. our

you my remarks that, our I very we remember, had is research well. on today work. And in if that mentioned we mentioned had launched enrollment That continues, So going last that continues. call the feasibility

Type are segment. expect, learning things the great We X we regarding and

those into for indications and which expansion pivotal label so will we drive And enter then learnings, will Omnipod study, the then from a in larger X.

over will the months So or play longer. potentially, coming out that is what year and a

believe given tremendous certainly X to bring a the Omnipod use. sharing value that. technology that and We experience and But haven’t Dr. We can segment with drive improved Bode tremendous to segment. Type outcomes, in this timeline be his his ease X on our of research will

And front. are to on so the we committed that doing great and partner he’s with us research, been a

Operator

Thank you.

question So Rose from go Canaccord. ahead. Kyle comes Please our next from

Kyle Rose

questions. Great. Thank the taking you much very for

remarks. say I in think the this, Shacey, you heard prepared I

me So you’ll Omnipod the pharmacy like if the but X OX correct I’m be or in channel. it sounded launching only wrong,

is drivers question more to it access the So is limited important the one, like one of guess sounded And two, launch. during that correct? going I then be

the So conversations X access you’ve some getting maybe just the the the solely driven time channel to pharmacy decision had side? help us think go and about your on that with for line to broader have payers in maybe pharmacy Omnipod of

Shacey Petrovic

you price correct will be launching in be that pharmacy will Kyle, that Sure. the X we channel, Omnipod we launching at heard parity. and

access. more we’ve a behind the made. was very more that And that to So decision thoughtful just access goal drive really is that rapid and affordable

pays a earlier, many bring we’re I And $XX less exciting a of going in users. what DASH because X mean, I to able same mentioned for really our advanced for remarkable is, so as user type means the what than it’s this in and users. technology, Omnipod actually means, for for average technology be month with MDI this today, on to the line co-pay

great So that a for a great is payers, really patients channel a do unlock for think to this channel population. exciting, and and truly for to It’s thing we right great the Insulet. channel

more talked into we’ve and we the channel, Omnipod for for benefits and as payers channel pharmacy driving X that the about, are frankly. that view great benefits an opportunity We users of has all into bring of patients, because to which

you will the access are primary right – So governor. and that be

the DASH, expect, launching with about it years plus you access, think DASH, and where all about we what broad And integrations we we so, and are pharmacies. us I wholesalers establish were DASH. channel, I of model and our – business range partnerships in we IT also think with back the doing a XX% to establishing were if would took with to established new X

and transferable now X. established that and work Omnipod for of is there All

good with are making conversations Our payers underway progress. and

we But covered indicator we we that’s so success think just as do move I access we rapidly primary that limited lives market all at we’re be to through is will expect will establish primary the more point, driver the of that’s be with this DASH. of performance than release. going how that And you doing the on because updating our

Operator

you. Thank

Steven question comes So Lichtman of our Please from Co. ahead. from the Oppenheimer next line & go

Steven Lichtman

Omnipod someone customers to access, potential Hi, getting you. for Shamcey, you off hold on is who everyone. it pharmacy that from moving any – would Omnipod customers for Thank thoughts Any DASH X for will will as it work yet them reason great? for new to PDM? on to in it from how is be or ramp Omnipod can’t pretty DASH that be X interested seamless there transition X

Shacey Petrovic

them Yes. No off. for to reason hold

to the and that. In pathways, the them when with on, get to foundation interface And DASH is about and for may we there sort I’ll fact, be user the reasons explain of is think training the is X. Omnipod foundation moving be Omnipod the user from, much training streamlined somebody example, who so Omnipod DASH for for likely for to is the experience more and X

headed but Omnipod may you up you certainly reason X, it off. to get to onto so no hold speed And if as Omnipod just DASH, help you’re

we who any that pump. or tube is whether Omnipod Omnipod said, we As Anybody, to that whether any a is legacy upfront be are DASH, MDI using frankly, is conversion charging not fee. or going technology,

fee rapidly. they to established access get and technology help out-of-pocket them, deploy worked our costs. to pharmacy really more have be upfront bring for strategy we able product reasonable to that more on hard the of kind as to soon very we’ve no and As conceive And of should to people with

Steven Lichtman

Shacey. Thanks,

Operator

you. Thank

line the comes from ahead. Please question Ravi Our Capital. go next Misra from of Berenberg

Ravi Misra

for Hi, you question. thanks Can the taking okay? me hear

Shacey Petrovic

got we you. Yes,

Ravi Misra

Hey, Thanks. great.

asked, So view. just very I’m – very kind Type asked, that jumping between But been I on been calls. I X adoption, commentary to this strong just if you’ve if wanted in impressive the seeing, my of sorry has

between some on seems can of as little what dynamics you in CGM for and or kind maybe to be the Is adoption bit the bringing that it of a you getting about help X your – easier help it both? like people here circle kind from Can And kind in a CGM victorious of access Abbott out terms the there kind a in usage is therefore, creating may CGM, pump tease get Just there going your into is you there of understand of it with – layering that’s this of guys adoption. doing of kind on more is leading X of work kind virtuous we cycle think and product to that’s Thanks. technology on them segment? of Type there? then how or maybe Type

Shacey Petrovic

Sure.

driving There I for we X for Type X channel have think And in first are, Type business the three all the things great right model observations view, the that in there. users. is my right are adoption Omnipod.

with fact very that can constraints this as provide we the few affordable, part So of access adoption. driving very what broad is

a our simplicity important is second CGM on third and really for And through is And of is awareness efforts both dynamic The this just the front. the marketing increasing the actually of our and sales adoption. technology, coming that’s us.

CGM Type years. sites as Type from monitoring we on patients, significantly, but really in set X glucose the about first Type in now benefiting more now XXXX, think just not have several is X their done blood population. in they population. have And X. we’ve dramatically the the the As next companies displace What been significantly And Type that and conversion X

and something psychological barrier. are wearing them they are data also over looking get and get in users because Omnipod for CGM in comfortable tools visibility how to to gotten these like them that range, spending As range, they time their are they has little help

technology the and are to drive think all So really things well helping in Type success of suited. those I X, our three is

in in see So this the for great market. further advancement is adoption trend us CGM, progress of as and a we

Operator

our Thank the question comes from go Antalffy SVB you. I show of last Danielle line Please Leerink. ahead. from

Danielle Antalffy

me Type put manages could stellar really good standard a Shacey, much MDIs or help actually broken down Hey, and question of everyone’s not what have population guys so penetration the you ultimate patient Type you that X you you for their to environment. that Thanks might barriers the think Sorry, way different on thinking how squeezing in there But thinking us for close versus was for mean regardless just penetration? be insulin-dependent X some reach given year I we so disease patients? pretty ultimate everyone. afternoon, from congrats should sentiment. an done given and patient they maybe the population on is this are a or should environment let’s perspective mean that to just there. think majority that about of we the be Can understand this echoing – well of you’ve care is pump, for I them? what relevant per long. you it,

Shacey Petrovic

sure. Yes, Sure.

take I on think segment. time going ultimate comment think won’t it’s just with penetration this to I I because

just days in the relative to segment. early here really Type We’re X

So we’re Xs we’re curve. because more that XX% and are saying, can comfortable adoption get over hey, where mature we we in Type see – we’re

user, they the got very to into seeing bring our and both argue, their simplicity we Type adoption, market, in an Type users that more the for we should the drive as adoption. important enthusiastic into think much precipice marketplace. this market, When further X the wave it. embraced. incredibly a we is and to but as doing that regardless, being then broad, user. of very unlock that But isn’t all Omnipod And to as about will X of accelerator for technologies start see important simple think continued And X as We’re user next and – And think – is I there segments, you X, intensively the we’re the all Type X product need. Type look today drive can kind unparalleled Xs, small establish particularly opportunity. the we Omnipod be think would bring that with as the then penetration we we advantages at really growth Type we’ve And work we for X in massive X, are X our it’s we’re simplicity Type we managed to great of that standing on different do affordable we than those the are, access of Type

we’re the excited X space. for about the prospects Type So long-term

Operator

Thank you. Shacey the would to to like conference This concludes our back Q&A session. Petrovic. I turn

Shacey Petrovic

us. it clinical what the investigators recently from X have families. for patients And with you. Desalvo, ameliorated. have about This outstanding I said he It’s anything one burden is Baylor, experienced And and what their of study, results, And only his but achieved has not customers diabetes on families. share that the I X their every feedback shared our you Thank Omnipod this us our to, was clear principal satisfaction Omnipod unlike to he single pivotal right Dr. he wanted is especially gets day. caregivers. is and been for is the about is that going before, our

progress of We proud we’ve are made. so the

We’re days now and million across changing globe, we’re not going to lives the still of days – the X.XX stop best customers’ and are ahead. Insulet people there. our

evening. Have great very you So much. thank a

you talk will quarter. We next to

Operator

day. Thank and Thank you. you conference. Ladies wonderful concludes for gentlemen, today’s a this have participation, and

may disconnect. all You

Insulet (PODD) 24 Feb 212020 Q4 Earnings call transcript